TRIQ · Searching for TRans-eQTL affecting the risk to develop Inflammatory Bowel Disease

Lines connect the coordinator with its partners.

Project objective

Inflammatory Bowel Disease, including Crohn’s disease and ulcerative colitis, now afflict close to 1/250 individuals in industrialized societies. There is a pressing need for effective preventive means as well as curative drugs. Cis-eQTL analyses are uncovering a growing list of genes that are perturbed by IBD risk variants detected by GWAS, constituting a list of prime drug targets for the pharmaceutical industry. Cis-eQTL effects trigger downstream effects – both within the same (intracellular) and other cell types (intercellular) – that culminate in disease declaration. Some of these downstream effects are accompanied by changes in transcript levels referred to as trans-eQTL effects. The aim of the TRIQ project is to take advantage of the CEDAR-II dataset – transcriptome data for up to 400 individuals in > 75 IBD-relevant cell types – to identify trans-eQTL effects that mediate IBD predisposition. The genes that are perturbed by these trans-effect will include druggable targets that constitute prime targets for the development of new IBD therapies.

Original text from CORDIS.

Participants

• UNIVERSITE DE LIEGE · LIEGECoordinatorBelgium

Links

• View on CORDIS
• DOI: 10.3030/101155061
• https://ec.europa.eu/research/participants/documents/downloadPublic?documentIds=080166e51f4bf5e3&appId=PPGMS